Linni Klaus, Ugurluoglu Ara, Hitzl Wolfgang, Aspalter Manuela, Hölzenbein Thomas
1 Department of Vascular and Endovascular Surgery, PMU Salzburg, Austria.
J Endovasc Ther. 2014 Aug;21(4):493-502. doi: 10.1583/14-4699R.1.
To compare clinical and hemodynamic outcome in patients undergoing treatment of common femoral artery (CFA) atherosclerotic lesions by bioabsorbable stent implantation (BASI group) or by common femoral artery endarterectomy (CFE group).
A randomized, controlled, single-center, open-label trial was initiated to compare outcomes of BASI or CFE in patients with chronic atherosclerotic occlusive lesions in the CFA. From May 2011 to April 2013, 116 consecutive patients were recruited; after excluding 36 patients, 80 patients (52 men; mean age 72.2±9.6 years) were enrolled 1:1 and are the subject of this intention-to-treat interim analysis (40 patients in each group). The primary endpoint was surgical site infections; secondary outcome measures were technical success, hemodynamic improvement, clinical improvement, patency, limb salvage, and survival.
There was no statistically significant difference between both groups regarding demographic data, cardiovascular risk factors, or CFA occlusions. The CFE patients presented with 7 surgical site infections (all minor) vs. none in the BASI group (p=0.002) and a longer mean postoperative hospital stay of 7 vs. 2 days for BASI patients (p<0.001). Technical success rates were 97.5% and 100% for the BASI and CFE groups, respectively. Postoperative ankle-brachial index means were comparable (p=0.38). The 30-day primary patency rates were 92.5% and 100% for the BASI and CFE groups, respectively (p=0.038). There were 6 reconstruction failures in CFE patients vs. none in the BASI group (p=0.02); 5 failures involved initial CFA occlusions. At 1 year, the primary and secondary patency rates were 80% vs. 100% (p=0.007) and 84% vs. 100% (p=0.01) for BASI and CFE patients, respectively. Limb salvage was equivalent, and survival rates were 88% and 90% for BASI vs. CFE patients (p=0.51) at 1 year.
This interim analysis suggests that BASI is not an option for CFA occlusion and is only a limited option for CFA stenosis. Clinical and hemodynamic results are comparable for BASI and CFE. An increased rate of redo procedures in the BASI patients outweighs lower surgical site infection rates compared to CFE. Short-term patency rates are significantly worse in patients undergoing CFA stenting with BASI.
比较通过生物可吸收支架植入术治疗股总动脉(CFA)动脉粥样硬化病变的患者(生物可吸收支架植入组,BASI组)与接受股总动脉内膜切除术的患者(CFE组)的临床和血流动力学结局。
启动一项随机、对照、单中心、开放标签试验,以比较BASI或CFE治疗CFA慢性动脉粥样硬化闭塞性病变患者的结局。2011年5月至2013年4月,连续招募了116例患者;排除36例患者后,80例患者(52例男性;平均年龄72.2±9.6岁)按1:1比例入组,为本意向性治疗中期分析的对象(每组40例患者)。主要终点是手术部位感染;次要结局指标包括技术成功率、血流动力学改善、临床改善、通畅率、肢体挽救率和生存率。
两组在人口统计学数据、心血管危险因素或CFA闭塞方面无统计学显著差异。CFE组患者出现7例手术部位感染(均为轻度),而BASI组无感染(p=0.002),BASI组患者术后平均住院时间为2天,CFE组为7天(p<0.001)。BASI组和CFE组的技术成功率分别为97.5%和100%。术后踝肱指数均值相当(p=0.38)。BASI组和CFE组的30天主要通畅率分别为92.5%和100%(p=0.038)。CFE组有6例重建失败,而BASI组无失败(p=0.02);5例失败涉及初始CFA闭塞。1年时,BASI组和CFE组患者的主要和次要通畅率分别为80%对100%(p=0.007)和84%对100%(p=0.01)。肢体挽救情况相当,1年时BASI组和CFE组患者的生存率分别为88%和90%(p=0.51)。
这项中期分析表明,BASI不是治疗CFA闭塞的选择,对于CFA狭窄只是有限的选择。BASI和CFE的临床和血流动力学结果相当。与CFE相比,BASI组患者再次手术率增加,超过了较低的手术部位感染率。接受BASI治疗CFA支架植入术的患者短期通畅率明显更差。